XML 21 R1.htm IDEA: XBRL DOCUMENT v3.25.4
Document and Entity Information - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2025
Feb. 20, 2026
Jun. 30, 2025
Document information      
Document Type 10-K    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2025    
Securities Act File Number 001-38492    
Entity Registrant Name Kiniksa Pharmaceuticals International, plc    
Entity Incorporation, State or Country Code X0    
Entity Tax Identification Number 98-1795578    
Entity Address, Address Line One 105 Piccadilly, Second Floor    
Entity Address, City or Town London    
Entity Address, Country GB    
Entity Address, Postal Zip Code W1J 7NJ    
City Area Code 781    
Local Phone Number 431-9100    
Title of 12(b) Security Class A Ordinary Shares    
Trading Symbol KNSA    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Error correction flag false    
Auditor Name PricewaterhouseCoopers LLP    
Auditor Firm ID 238    
Auditor Location Boston, Massachusetts    
Entity Shell Company false    
Entity Public Float     $ 1,114.0
Current Fiscal Year End Date --12-31    
Document Fiscal Year Focus 2025    
Document Fiscal Period Focus FY    
Entity Central Index Key 0001730430    
Amendment Flag false    
Documents Incorporated by Reference

Portions of the registrant’s definitive proxy statement for its 2026 Annual Meeting of Shareholders, which the registrant intends to file with the Securities and Exchange Commission pursuant to Regulation 14A within 120 days after the end of the registrant’s fiscal year ended December 31, 2025, are incorporated by reference into Part III of this Annual Report on Form 10-K.

    
Ordinary Shares      
Document information      
Entity Common Stock, Shares Outstanding   76,535,377  
Class A ordinary shares      
Document information      
Entity Common Stock, Shares Outstanding   45,900,637  
Class B ordinary shares      
Document information      
Entity Common Stock, Shares Outstanding   1,795,158  
Class A1 ordinary shares      
Document information      
Entity Common Stock, Shares Outstanding   12,781,964  
Class B1 ordinary shares      
Document information      
Entity Common Stock, Shares Outstanding   16,057,618